Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5

2016-03-01

Additional Metadata
Persistent URL	doi.org/10.1016/j.eururo.2015.07.024, hdl.handle.net/1765/85472
Journal	European Urology : Official Journal of the European Association of Urology
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	van Soest, R.J, de Morrée, E.S, Kweldam, C.F, Wiemer, E.A.C, Mathijssen, A.H.J, de Wit, R, & van Weerden, W.M. (2016). Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. European Urology : Official Journal of the European Association of Urology, 69(3), e43–e44. doi:10.1016/j.eururo.2015.07.024

Publication